ConductScience.org, home

Paper40051146

Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds.

Adhikari A and 1 other. Small, 2025. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds. Papers, record 40051146. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40051146

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds.
PubMed
Journal
Small
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
8.84, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Adhikari AAniruddhahttps://orcid.org/0000-0001-6470-4099
2Chen IAIrene Ahttps://orcid.org/0000-0001-6040-7927

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NanoparticlesMajor topic
Antibodies, MonoclonalMajor topic
Humans
Animals

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R35 GM148249NIGMS NIH HHSUnited StatesR35GM148249PubMed and NIH
R35GM148249NIGMS NIH HHSUnited StatesR35GM148249PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References301

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123891990Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.Nanomedicine2014https://conductscience.org/library/papers/23891990PubMed
228187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
321039191Antibody engineering promotes nanomedicine for cancer treatment.Nanomedicine (Lond)2010https://conductscience.org/library/papers/21039191PubMed
423670869Future of the particle replication in nonwetting templates (PRINT) technology.Angew Chem Int Ed Engl2013https://conductscience.org/library/papers/23670869PubMed
533615202Dissecting the impact of target-binding kinetics of protein binders on tumor localization.iScience2021https://conductscience.org/library/papers/33615202PubMed
620134491Optimizing the safety of biologic therapy for IBD.Nat Rev Gastroenterol Hepatol2010https://conductscience.org/library/papers/20134491PubMed
738324463PD-L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self-Delivery.Adv Healthc Mater2024https://conductscience.org/library/papers/38324463PubMed
830844256pH Impacts the Orientation of Antibody Adsorbed onto Gold Nanoparticles.Bioconjug Chem2019https://conductscience.org/library/papers/30844256PubMed
927348241Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.ACS Appl Mater Interfaces2016https://conductscience.org/library/papers/27348241PubMed
1025305336Lessons from patient-derived xenografts for better in vitro modeling of human cancer.Adv Drug Deliv Rev2014https://conductscience.org/library/papers/25305336PubMed
1133277608Engineering precision nanoparticles for drug delivery.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33277608PubMed
1221223986A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro.J Control Release2011https://conductscience.org/library/papers/21223986PubMed
1317069527Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.Expert Rev Anticancer Ther2006https://conductscience.org/library/papers/17069527PubMed
1422493784Predictive in vivo animal models and translation to clinical trials.Drug Discov Today2012https://conductscience.org/library/papers/22493784PubMed
1511144234Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer.J Drug Target2000https://conductscience.org/library/papers/11144234PubMed
1639663706Conjugation Chemistry Markedly Impacts Toxicity and Biodistribution of Targeted Nanoparticles, Mediated by Complement Activation.Adv Mater2025https://conductscience.org/library/papers/39663706PubMed
1719664713Structure and function of the blood-brain barrier.Neurobiol Dis2010https://conductscience.org/library/papers/19664713PubMed
1819509221Bispecific T-cell engaging antibodies for cancer therapy.Cancer Res2009https://conductscience.org/library/papers/19509221PubMed
192384160Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes.FEBS Lett1990https://conductscience.org/library/papers/2384160PubMed
2038724718Computational design of non-porous pH-responsive antibody nanoparticles.Nat Struct Mol Biol2024https://conductscience.org/library/papers/38724718PubMed

See all 301 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42950029Nanomaterial-genetics enables near-infrared-driven genetically targeted neuromodulation.Sci Adv2026https://conductscience.org/library/papers/42950029PubMed
42824429Ultrahigh-DAR antibody-drug conjugates: advancing the next generation of targeted therapy.Antib Ther2026https://conductscience.org/library/papers/42824429PubMed
42700201Metal nanoparticles as next-generation therapeutics against antimicrobial resistance: mechanisms, functionalization, and translational potential.Mol Biol Rep2026https://conductscience.org/library/papers/42700201PubMed
42588669Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment.Cancers (Basel)2026https://conductscience.org/library/papers/42588669PubMed
42286319Reprogramming immunity: the promise and challenges of CAR T cell therapy in multiple sclerosis.Inflammopharmacology2026https://conductscience.org/library/papers/42286319PubMed
42193283Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines2026https://conductscience.org/library/papers/42193283PubMed
42079870Antibody-drug conjugates for infectious and neglected tropical diseases: chemical design principles, target biology, and translational challenges.Front Chem2026https://conductscience.org/library/papers/42079870PubMed
42076087Surface-Modified Polymeric Nanoparticles for Glioblastoma Therapy: A Review on Targeting Strategies and Delivery of Repurposed Drugs and Off-Label Non-Alkylating Agents.Pharmaceutics2026https://conductscience.org/library/papers/42076087PubMed
41853243Liposome-mediated gene delivery: A comprehensive review of biophysical parameters, lipid composition and targeting strategies.ADMET DMPK2026https://conductscience.org/library/papers/41853243PubMed
41834375Balancing Multivalent Avidity and Receptor Availability Governs mRNA Delivery by Antibody-Functionalized Lipid Nanoparticles.Nano Lett2026https://conductscience.org/library/papers/41834375PubMed
41749221Engineering integrin αvβ8-targeted extracellular vesicles to deliver BDNF mRNA for motor recovery in spinal cord injury.J Nanobiotechnology2026https://conductscience.org/library/papers/41749221PubMed
41709436Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.Microbiologyopen2026https://conductscience.org/library/papers/41709436PubMed
41601298Chelation-Controlled Oriented and Irreversible Immobilization of Native Antibodies on Photoreactive Magnetic Nanoparticles.ACS Appl Bio Mater2026https://conductscience.org/library/papers/41601298PubMed
41560793Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Mater Today Bio2026https://conductscience.org/library/papers/41560793PubMed
41524227Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41524227PubMed
41409587Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to overcoming tyrosine kinase inhibitor resistance.Bioimpacts2025https://conductscience.org/library/papers/41409587PubMed
41363830Emerging Advances in Nanomedicine for Targeted Cancer Photoimmunotherapy and Photo-Immunometabolic Therapy.Wiley Interdiscip Rev Nanomed Nanobiotechnol2025https://conductscience.org/library/papers/41363830PubMed
41184856Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Mol Cancer2025https://conductscience.org/library/papers/41184856PubMed
41035645Cell death mechanisms induced by gold nano-immunoconjugates-mediated photodynamic therapy against human oesophageal cancer stem cells.Front Immunol2025https://conductscience.org/library/papers/41035645PubMed
41012501Strategic and Chemical Advances in Antibody-Drug Conjugates.Pharmaceutics2025https://conductscience.org/library/papers/41012501PubMed

See all 24 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40051146

GET https://conductscience.org/api/papers/v1/40051146/references?page=2